Urology. 2006 Apr;67(4):731-6; discussion 736.
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
Rackley R, 037 STUDY GROUP.
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, U
SA. To evaluate the efficacy and tolerability of nighttime tolterodine dosing on urgency-related micturitions in patients with overactive bladder (OAB) and nocturia.
This was a 12-week randomized controlled study of 850 patients given 4 mg tolterodine extended release (TER) or placebo once daily 4 hours or less before bed. Patients with eight or more micturitions/24 hours and a mean of 2.5 episodes/night or more were included. Changes in the number of nighttime and 24-hour micturitions were analyzed by urgency rating per micturition. The urgency per micturition was recorded in 7-day diaries using a 5-point rating scale (score 1 to 5). Each micturition was classified according to the following urgency rating categories: total (1 to 5), non-OAB (1 to 2), or OAB (3 to 5). OAB-related micturitions were further classified as nonsevere (score 3) and severe (score 4 to 5). TER reduced the total number of nocturnal micturitions, but, compared with placebo, this difference was not statistically significant. However, TER did significantly reduce OAB-related and severe OAB-related nocturnal micturitions compared with placebo. TER had no effect on non-OAB micturitions. TER significantly reduced the total, OAB, and severe OAB micturitions during 24-hour and daytime intervals compared with placebo. Significantly more TER-treated than placebo-treated patients reported a treatment benefit and willingness to continue treatment. Adverse events associated with nighttime dosing of TER versus placebo were few. TER significantly reduced OAB-related micturitions during 24-hour, daytime, and nighttime intervals. TER did not affect normal (non-OAB) micturitions. Nighttime dosing with TER was associated with few adverse events and adverse event-related withdrawals. The 24-hour efficacy of TER was maintained with nighttime dosing.
Please click on the required question. Thank
you for choosing to visit us. This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT. I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.Authors:
Objectives:
Methods:
Results:
Conclusions:
- Introduction
- Abortion
- Amenorrhoea
- Birth Control
- Bladder Symptoms
- Cystitis
- Honeymoon Cystitis
- Urinary Tract Infection
- Frequency and Nocturia
- Urinary Incontinence
- Urge Incontinence
- Urodynamic Studies
- Bladder Training
- Oxybutinin
- Vesicare / Solfenacin
- Stress Incontinence
- Kegel Exercises
- TVT
- Overactive Bladder Syndrome
- Cancer in Women
- Childbirth
- Children and Teenagers
- Diet / Weight Loss
- Dysmenorrhoea
- Endometriosis
- Fibroids
- HRT
- Hirsutism
- Hysterectomy
- Infections
- Infertility
- Medication Drugs
- Menopause
- Menorrhagia
- Miscarriage
- Painful Sex
- Pap Smear Test
- PCOS
- Pelvic Pain
- PMS
- Postpartum
- Pregnancy
- Self Esteem
- Sexual Problems
- Vaginal Discharge
- Vaginal Prolapse
- Vulval Symptoms
Underperforming Family Website?
This website
2womenshealth.com
is the
most popular personal website
in its category
1.5 million visitors annually.
The author has applied
his clinical and
scientific research experience
to
the application of techniques to
promote your web pages.
Visit
Now
Promote Your
Family Website
Improve Your Business Income
